Markets

Ginkgo Bioworks (DNA) Partners with Merck to Revolutionize Biologic Manufacturing

Published

11 months ago

August 7, 2023

Ginkgo Bioworks (NYSE: DNA), a pioneering biotechnology company at the forefront of cell programming and biosecurity, has taken a significant stride towards advancing biologic manufacturing by announcing a groundbreaking collaboration with Merck (known as MSD outside of the United States and Canada). The partnership aims to revolutionize biologic drug production by leveraging Ginkgo’s cutting-edge platform and Merck’s expertise in pharmaceutical development.

The strategic alliance, officially unveiled today, represents a formidable force in the biotechnology industry, with both companies bringing their unique strengths to the table. Ginkgo Bioworks, renowned for its advanced cell programming technology, is dedicated to engineering organisms to produce valuable compounds, while Merck has established itself as a global pharmaceutical giant, known for its extensive experience in drug research, development, and manufacturing.

Want HOT Stock Alerts?

Text “STOCKS” to 855-261-8342

At the core of this collaboration lies the pursuit of improving biologic manufacturing processes. Biologics, which are therapeutic drugs derived from living organisms, have demonstrated tremendous potential in treating a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. However, their complex nature and sensitive production requirements often present challenges in large-scale manufacturing.

Ginkgo will leverage its proprietary cell programming platform, which enables precise engineering and control of microorganisms, to optimize the production of biologics. By harnessing the power of synthetic biology, the company aims to enhance the efficiency, scalability, and cost-effectiveness of biologic drug manufacturing processes.

As part of the partnership, Merck will contribute its vast experience in the pharmaceutical industry, providing invaluable insights into drug development and regulatory requirements. By combining their expertise, Ginkgo and Merck aim to accelerate the discovery and development of new biologic drugs and streamline their manufacturing to reach patients in need more efficiently.

Want HOT Stock Alerts?

Text “STOCKS” to 855-261-8342

Jason Kelly, CEO and Co-founder of Ginkgo Bioworks, expressed his enthusiasm about the collaboration, stating, “We are thrilled to join forces with Merck, a world leader in pharmaceuticals, to address the challenges in biologic drug manufacturing. By bringing together Ginkgo’s cutting-edge technology and Merck’s vast expertise, we can significantly advance the production of life-saving therapies and make them more accessible to patients worldwide.”

In addition to optimizing existing biologic manufacturing processes, the partnership will also focus on exploring new avenues for drug development and delivery. The synergistic collaboration between Ginkgo and Merck is expected to foster a more robust pipeline of biologics with diverse applications across various therapeutic areas.

Both companies share a strong commitment to biosecurity, ensuring that their technologies and manufacturing processes uphold the highest safety standards and mitigate any potential risks associated with biotechnology advancements.

The news of the collaboration has been met with enthusiasm and anticipation from investors and industry experts alike, with Ginkgo Bioworks’ stock (NYSE: DNA) experiencing a surge in value following the announcement.

The joint efforts of Ginkgo Bioworks and Merck hold the promise of propelling the biotechnology industry forward, bringing us closer to a future where groundbreaking biologic drugs are more efficiently developed, manufactured, and made available to patients globally.

Markets

What's Going On With Broadcom Inventory On Tuesday?

Published

21 mins ago

June 26, 2024

Sir Chartist

What's Going On With Broadcom Stock On Tuesday?

What’s Going On With Broadcom Inventory On Tuesday?

Broadcom Inc (NASDAQ:) just lately introduced vital updates to its VMware Cloud Basis (VCF), aiming to reinforce digital innovation with sooner infrastructure modernization, improved developer productiveness, and higher cybersecurity at a low .

The most recent developments in VCF assist clients’ wants by integrating enterprise-class computing, networking, storage, administration, and safety throughout numerous environments.

The brand new VCF Import performance permits seamless integration of present vSphere and vSAN environments into VCF, optimizing sources with no need an entire rebuild.

This may considerably improve effectivity, decrease prices, and pace up time to worth.

place because the second-largest AI semiconductor provider globally, trailing solely Nvidia Corp (NASDAQ:).

They famous the corporate’s dominant market share of roughly 55-60% in customized (ASIC) chip designs market projected to develop at a compound annual progress fee (CAGR) of over 20%, presenting a $20 billion to $30 billion alternative.

Analysts predict Broadcom will drive $11 billion to $12 billion in AI revenues in 2024, with additional progress to $14 billion to $15 billion in 2025.

This optimism is fueled by main tech firms’ growing give attention to customized ASIC options for AI computing wants.

Worth Motion: AVGO shares traded greater by 0.30% at $1,596.78 on the final examine on Tuesday.

Disclaimer: This content material was partially produced with the assistance of AI instruments and was reviewed and revealed by Benzinga editors.

Photograph by way of Shutterstock

“ACTIVE INVESTORS’ SECRET WEAPON” Supercharge Your Inventory Market Recreation with the #1 “information & every thing else” buying and selling software: Benzinga Professional –

Get the newest inventory evaluation from Benzinga?

This text initially appeared on

Markets

Tencent's 'Dungeon & Fighter' recreation dominates China's cell obtain charts

Published

24 mins ago

June 26, 2024

Sir Chartist

BEIJING (Reuters) – Tencent Holdings (OTC:) Ltd’s newly launched “Dungeon & Fighter” (DnF Cell) has acquired off to a powerful begin, dominating top-grossing charts on Apple (NASDAQ:)’s iOS platform in China for practically a month, trade information confirmed.

The sport, launched on this planet’s greatest gaming market on Might 21, broke the $100 million income mark in simply 10 days, in accordance with a report launched by information analytics agency Sensor Tower this week.

It additionally topped the worldwide cell recreation income progress chart for Might and ranked eighth in total income.

Within the first 10 days of its launch, DnF Cell’s income in China’s iOS market surpassed the mixed earnings of Tencent’s different in style titles “Honor of Kings” and “PUBG Cell,” in accordance with a separate Sensor Tower report dated June 17.

This surge contributed to a 12% progress in Tencent’s cell recreation income in Might, in accordance with Sensor Tower.

The DnF Cell title, based mostly on a preferred PC franchise, had been obtainable internationally for years. Its China launch was delayed as a result of Beijing’s non permanent freeze on new recreation approvals.

DnF Cell’s early success comes amid ongoing tensions between Tencent and smartphone distributors over gaming income sharing.

Earlier this month, Tencent pulled the sport from chosen Android app shops, citing contract expiries.

Recreation builders in China have lengthy had a contentious relationship with distributors over points corresponding to income sharing, as cell video games change into more and more in style within the broader recreation market. The usual 50% income break up has typically been a bone of competition.

Markets

Steve Eisman Says the Nvidia Story Is Going to Final for Years

Published

1 hour ago

June 26, 2024

Sir Chartist

(Lusso’s Information) — A $430 billion sell-off earlier this week in artificial-intelligence darling Nvidia Corp. was not more than a blip to Neuberger Berman Group’s Steve Eisman.

Most Learn from Lusso’s Information

The senior portfolio supervisor, finest identified for his “Massive Quick” wager in opposition to subprime mortgages forward of the worldwide monetary disaster, owns “loads” of the chipmaker’s shares and considers it a long-term play that’s going to be related for years to come back, he mentioned Tuesday in an an interview on Lusso’s Information Tv.

Merchants appeared to share his view Tuesday because the inventory rallied 6.8%, climbing again from a three-day slide that pushed shares down greater than 10% for the primary time since April, previous the brink that represents a correction.

“When you take a look at the chart on Nvidia, you may barely see the correction,” Eisman mentioned. “I don’t assume it means something.”

The AI poster-child has soared this yr amid a livid urge for food for its chips that dominate the marketplace for artificial-intelligence computing. Its newest climb noticed shares surge 43% from its Could 22 earnings report and stock-split announcement to the June 18 peak, when it toppled Microsoft Corp. to turn into the world’s Most worthy firm — a title it has since misplaced.

Nvidia remains to be up 155% this yr via Tuesday’s shut. As some skeptics fear that the corporate has grown too rapidly, Eisman says worth is the very last thing to worry over.

“One of many issues I realized working a hedge fund is that shorting a inventory solely due to valuation is a dying want,” he mentioned, including that individuals buy a inventory even when it’s perceived to be costly as a result of they’re shopping for right into a story. “So long as the story is unbroken — like Nvidia is clearly intact — the story goes to proceed. I don’t assume all that a lot in regards to the valuation of Nvidia.”

The message that Nvidia will proceed to learn from booming AI demand was echoed by Nuveen Asset Administration LLC’s chief funding officer.

“Nvidia is the corporate that wins on this house, principally it doesn’t matter what,” Saira Malik mentioned in an interview. “Everybody who desires to shift into AI principally has to make use of Nvidia’s merchandise. Their development price has been so sturdy that their price-to-earnings actually isn’t costly.”

Malik is a portfolio supervisor for a number of key funding methods for Nuveen, a $1.3 trillion international asset supervisor. The $125 billion Faculty Retirement Equities Fund – Inventory Account, which she oversees, has outperformed 86% of friends over the previous yr, in keeping with knowledge compiled by Lusso’s Information. Microsoft, Nvidia, Apple Inc. and Amazon.com Inc. had been the fund’s largest holdings as of the top of Could.

“Individuals will say the inventory worth itself has simply carried out so effectively, how are you going to personal it?” Malik mentioned. When in comparison with friends, “it’s not an costly inventory.”

Whereas Nvidia trades at a premium of about 50% to the Nasdaq 100 Index, its 12-month ahead price-to-earnings ratio has pulled again from a 2023 excessive of 63 instances right down to about 40. It’s now valued near friends corresponding to Superior Micro Gadgets Inc. Malik mentioned the AI-fueled rally in Nvidia and Microsoft — which has propelled US inventory benchmarks to a collection of file highs — is in contrast to the dot-com bubble.

“These corporations are far more dominant as a result of they aren’t model new,” she mentioned. “They’ve been round for years investing on this pattern. So I do assume it’s completely different this time.”

–With help from Jeran Wittenstein, Ryan Vlastelica, Lisa Abramowicz, Annmarie Hordern and Dani Burger.

(Updates with Tuesday’s inventory transfer.)

Most Learn from Lusso’s Information Businessweek